Candesartan improves impaired endothelial function in the human coronary artery

Iino, Kenji; Watanabe, Hiroyuki; Iino, Takako; Katsuta, Mitsuaki; Koyama, Takashi; Kosaka, Toshimitsu; Terui, Gen; Ito, Hiroshi

doi:10.1097/mca.0b013e328351ab42

Cited by 8 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it may be noted that Framingham Heart Study researchers have recently suggested that impaired vascular function may contribute to increase in cardiovascular risk by promoting exaggerated BP responses during the physical activities of daily living 18. Reports that angiotensin-receptor blockers can ameliorate both these aspects of vascular dysfunction19–22 may therefore be supportive of a degree of treatment-specific benefit (although, see Sozen et al23 for reservations that any effect on endothelial function may not be sustained in long-term clinical use).…”

Section: Discussionmentioning

confidence: 99%

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Petrella¹,

Tremblay²,

Backer

et al. 2014

VHRM

View full text Add to dashboard Cite

Purpose/introductionThe Canadian Hypertension Education Program (CHEP) has identified blood pressure (BP) control as a key target for an overall reduction in cardiovascular disease risk. The POWER survey (Physicians’ Observational Work on Patient Education According to their Vascular Risk) used Framingham methodology to investigate the impact of an angiotensin-receptor-blocker-based regimen on arterial BP and total coronary heart disease (CHD) risk in a subset of patients recruited in Canada.Methods309 Canadian practices screened for patients with either newly diagnosed or uncontrolled mild/moderate hypertension (sitting systolic blood pressure [SBP] >140 mmHg with diastolic blood pressure [DBP] <110 mmHg). Treatment comprised eprosartan 600 mg/day with add-on antihypertensive therapy after 1 month if required. The primary efficacy variable was change in SBP at 6 months; the secondary variable was the absolute change in the Framingham 10-year CHD risk score.Results1,385 patients were identified, of whom 1,114 were included in the intention-to-treat (ITT) cohort. Thirty-eight point four percent of ITT patients were managed with monotherapy at 6 months, versus 35.2% and 13.7% with two-drug or multiple-drug therapy, respectively. SBP in the ITT cohort declined 22.4 (standard deviation [SD] 14.8) mmHg and DBP declined 10.5 (SD 10.3) mmHg during that time. The absolute mean Framingham score declined 2.1 (SD 3.1) points with significant age and sex variation (P<0.001) and differences between the various Framingham methods used.Discussion/conclusionPrimary care physicians were able to use a strategy of BP lowering and CHD risk assessment to achieve significant reductions in BP and Framingham-assessed CHD risk. The effect size estimate of the different Framingham methods varied noticeably; reasons for those differences warrant further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Petrella¹,

Tremblay²,

Backer

et al. 2014

VHRM

View full text Add to dashboard Cite

show abstract

“…116 Angiotensin (AngII) receptor blockers alter endothelial dysfunction in coronary artery disease. 117 Vascular dysfunction occurs in the presence of AngII, which is also released in hypovolaemic states. 118 Nonetheless, in one study, there were no statistically significant differences in circulating levels of renin and AngII among normal-tension glaucoma patients and normal controls.…”

Section: Disorders Of the Optic Nervementioning

confidence: 99%

“…Patients with normal‐tension glaucoma have altered vasoreactivity to endothelin‐1 . Angiotensin (AngII) receptor blockers alter endothelial dysfunction in coronary artery disease . Vascular dysfunction occurs in the presence of AngII, which is also released in hypovolaemic states .…”

Section: Search Strategymentioning

confidence: 99%

Hydration, fluid regulation and the eye: in health and disease

Sherwin

Kokavec

Thornton

2015

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Variation in systemic hydration status, namely chronic systemic hypohydration or dehydration, can influence the development of several chronic non-ophthalmic diseases. Owing to the eye's high water content and unique system of fluid regulation, we hypothesized that hydration status may affect the eye in health and disease states. Therefore, we performed a systematic review of the current evidence implicating changes in hydration and their association with ocular physiology and morphological characteristics. We also reviewed relevant clinical correlations of changes in hydration and major common eye diseases. Our findings suggest that systemic hydration status broadly affects a variety of ocular pathophysiologic processes and disease states. For example, dehydration may be associated with development of dry eye syndrome, cataract, refractive changes and retinal vascular disease. On the other hand, excessive hydration is associated with some ocular diseases. Tear fluid osmolarity may be an effective marker of systemic hydration status. Recent studies implicate chronic renin-angiotensin-aldosterone system activation in the pathogenesis of diabetic retinopathy and glaucoma but also suggest its antagonism may be a useful therapeutic target. Our findings indicate that assessment of hydration status may be an important consideration in the management of patients with chronic eye diseases and undergoing eye surgery. Further research investigating the role of acute and chronic changes in hydration in individuals with and without ocular disease is warranted.

show abstract

“…Angiotensin II type1 receptor blockers (ARB) are suspected to improve coronary endothelial function by improving the NO bioavailability 38. However, the renin-angiotensin system (RAS) with its active peptide Angiotensin II is a major determinant in cardiac remodelling and thus, RAS blockade by candesartan attenuates remodelling.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular drugs attenuated myocardial resistance against ischaemia-induced and reperfusion-induced injury in a rat model of repetitive occlusion

et al. 2018

View full text Add to dashboard Cite

ObjectiveWe investigated the impact of cardioprotective drugs on ST-elevation, arrhythmias and infarct size in a rat model of repetitive coronary artery occlusion.MethodsSeventy Sprague-Dawley rats were randomised to two control and five treatment groups. Placebo was either implantation of a pneumatic occluder onto the left anterior descending coronary artery (LAD) without starting repetitive occlusion (SHAM) or subsequent RO of the LAD over 10 days without medication (ROP). Treatment groups underwent RO and additionally received nitroglycerin (NTG), metoprolol, verapamil (VER), ranolazine (RAN) or candesartan (CAN). Two weeks after the intervention, rats underwent a single, sustained LAD occlusion followed by reperfusion. To evaluate differences in cardiac resistance against myocardial ischaemia and reperfusion injury, cardiac surrogate parameters including maximal ST-elevation, arrhythmias and infarct size were assessed.ResultsCompared with sham, RO alone and RO plus nitroglycerin were associated with significantly lower maximal ST-elevation and percentage of infarcted myocardium (SHAM 0.12 mV, ROP 0.06 mV (p=0.004), NTG 0.05 mV (p=0.005); SHAM 16.2%, ROP 6.6% (p=0.008), NTG 5.9% (p=0.006). Compared with RO alone, RO plus RAN was accompanied by increased ST-elevation (0.13 mV, p=0.018) and RO plusVER or CAN by more infarcted myocardium (14.2%, p=0.004% and 15.5%, p=0.003, respectively). Rats treated with VER, RAN or CAN tended to severe arrhythmias more frequently than those of the control groups.ConclusionsRO led to an increased myocardial resistance against ischaemia and reperfusion injury. Concomitant administration of nitroglycerin did not affect the efficacy of RO. Cardiovascular channel or receptor blockers reduced the efficacy of RO.

show abstract

Candesartan improves impaired endothelial function in the human coronary artery

Abstract: Our results suggest that candesartan improves coronary endothelial dysfunction of human coronary arteries and may prevent cardiac events.

Cited by 8 publications

References 28 publications

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Hydration, fluid regulation and the eye: in health and disease

Cardiovascular drugs attenuated myocardial resistance against ischaemia-induced and reperfusion-induced injury in a rat model of repetitive occlusion

Contact Info

Product

Resources

About